Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2019
Context: The filing discloses interim data from a Phase 1 study of the Company's personalized cancer vaccine (mRNA-4157) presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. It also references early data from a National Cancer Institute (NCI) study of a related vaccine (mRNA-4650).
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial data and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event is the release of clinical data:
- Moderna mRNA-4157: Interim data from a Phase 1 study was announced.
- NCI mRNA-4650: Early data from four patients with advanced metastatic cancers showed the vaccine was safe at dose levels of 0.13 mg and 0.39 mg with no dose-limiting toxicities or grade 3/4 adverse events.
- Immunogenicity: The NCI detected neoantigen-specific CD4 and CD8 T-cell responses in three of the four patients evaluated.
Guidance, Outlook, and Risks
Outlook: Immunogenicity analysis for the fourth patient in the NCI study is ongoing. The NCI program utilizes Moderna's mRNA technology but employs a different neoantigen selection process and study design than Moderna's own Phase 1 mRNA-4157 study.
Risks/Contingencies: The filing explicitly states that the information provided in Item 7.01 and the accompanying exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (ASCO Presentation Slides) for detailed clinical data not fully summarized in the 8-K text.
- Verify the distinction between Moderna's mRNA-4157 study and the NCI's mRNA-4650 study regarding neoantigen selection and design.
- Monitor future filings for the completion of immunogenicity analysis for the fourth patient in the NCI study.
- Check subsequent 10-Q or 10-K filings for financial impacts or updates on the commercialization timeline of the personalized cancer vaccine.
